Case Report

被引:6
作者
Kalinowski, Anne H. [1 ]
Quint, Elisabeth H. [2 ]
Weyand, Angela C. [3 ]
机构
[1] Univ Michigan, Med Sch, 1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA
[2] Univ Michigan, Dept Obstet & Gynecol, Med Sch, Ann Arbor, MI 48109 USA
[3] Univ Michigan, Dept Pediat, Med Sch, Ann Arbor, MI 48109 USA
关键词
choices; monitoring; and managing iron levels; Pediatric; Dysmenorrhea; Hereditary hemochromatosis; von Willebrand disease; IRON OVERLOAD; DEFERASIROX;
D O I
10.1016/j.jpag.2020.10.003
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Background: Hereditary hemochromatosis typically presents in adulthood with organ damage secondary to iron overload. In women, menstrual periods are a protective mechanism allowing for monthly loss of iron stores. Case: We report the case of a female adolescent whose family history, clinical presentation, and laboratory investigation revealed a diagnosis of hereditary hemochromatosis and von Willebrand disease. For control of heavy menstrual bleeding, menstrual suppression was started with a subsequent increase of her ferritin levels. Summary and Conclusion: No significant data exist regarding the management of women with hereditary hemochromatosis who require menstrual suppression. This case highlights the difficulty in balancing the need for hormonal menstrual suppression with its effect on treatment choices, monitoring, and managing iron levels.
引用
收藏
页码:74 / 76
页数:3
相关论文
共 8 条
[1]  
[Anonymous], 2010, ACOG Practice Bulletin No. 110. Obstetrics and Gynecology
[2]   Diagnosis and Management of Hemochromatosis: 2011 Practice Guideline by the American Association for the Study of Liver Diseases [J].
Bacon, Bruce R. ;
Adams, Paul C. ;
Kowdley, Kris V. ;
Powell, Lawrie W. ;
Tavill, Anthony S. .
HEPATOLOGY, 2011, 54 (01) :328-343
[3]   Deferasirox in patients with iron overload secondary to hereditary hemochromatosis: results of a 1-yr Phase 2 study [J].
Cancado, Rodolfo ;
Melo, Murilo R. ;
Bastos, Roberto de Moraes ;
Santos, Paulo C. J. L. ;
Guerra-Shinohara, Elivira M. ;
Chiattone, Carlos ;
Ballas, Samir K. .
EUROPEAN JOURNAL OF HAEMATOLOGY, 2015, 95 (06) :545-550
[4]  
Klaassen Robert J, 2002, Paediatr Child Health, V7, P245
[5]   Aspects of the laboratory identification of von Willebrand disease in women [J].
Kouides, Peter A. .
SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2006, 32 (05) :480-484
[6]   ACG Clinical Guideline: Hereditary Hemochromatosis [J].
Kowdley, Kris V. ;
Brown, Kyle E. ;
Ahn, Joseph ;
Sundaram, Vinay .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2019, 114 (08) :1202-1218
[7]   A Phase 1/2, Dose-Escalation Trial of Deferasirox for the Treatment of Iron Overload in HFE-Related Hereditary Hemochromatosis [J].
Phatak, Pradyumna ;
Brissot, Pierre ;
Wurster, Mark ;
Adams, Paul G. ;
Bonkovsky, Herbert L. ;
Gross, John ;
Malfertheiner, Peter ;
McLaren, Gordon D. ;
Niederau, Claus ;
Piperno, Alberto ;
Powell, Lawrie W. ;
Russo, Mark W. ;
Stoelzel, Ulrich ;
Stremmel, Wolfgang ;
Griffel, Louis ;
Lynch, Nicola ;
Zhang, Yiyun ;
Pietrangelo, Antonello .
HEPATOLOGY, 2010, 52 (05) :1671-1679
[8]   Prevalence of CY282Y and H63D mutations in the hemochromatosis (HFE) gene in the United States [J].
Steinberg, KK ;
Cogswell, ME ;
Chang, JC ;
Caudill, SP ;
McQuillan, GM ;
Bowman, BA ;
Grummer-Strawn, LM ;
Sampson, EJ ;
Khoury, MJ ;
Gallagher, ML .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (17) :2216-2222